Location · San Antonio, TX
Clinical trials in San Antonio, TX
347 recruiting studies have a site in the San Antonio area, and 68 of them accept healthy volunteers. The area includes New Braunfels, Schertz, Boerne, Live Oak, Universal City and nearby cities.
347 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
More recruiting studies (pay not posted)
- RecruitingPhase 2
DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.
Incannex Healthcare Ltd
- Location
- Chula Vista, CA + 11 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
Axsome Therapeutics, Inc.
- Location
- Dothan, AL + 28 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
Axsome Therapeutics, Inc.
- Location
- Dothan, AL + 27 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 14 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
Novartis Pharmaceuticals
- Location
- Memphis, TN + 2 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
Novartis Pharmaceuticals
- Location
- Tampa, FL + 6 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Incyte Corporation
- Location
- Birmingham, AL + 36 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2/Phase 3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc.
- Location
- Cullman, AL + 32 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Incyte Corporation
- Location
- Birmingham, AL + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
AstraZeneca
- Location
- Cullman, AL + 53 other US sites
- Eligibility basics
- Ages 40–80
- Recruiting
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Tempus AI
- Location
- Birmingham, AL + 39 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated…
Eccogene
- Location
- Chandler, AZ + 65 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
Genentech, Inc.
- Location
- Peoria, AZ + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Eli Lilly and Company
- Location
- Fremont, CA + 8 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
UCB Biopharma SRL
- Location
- Miami, FL + 6 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Regeneron Pharmaceuticals
- Location
- Peoria, AZ + 34 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Phoenix, AZ + 44 other US sites
- Eligibility basics
- Ages 12+
- Recruiting
The PERSEVERE Study
Inari Medical
- Location
- New Haven, CT + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Takeda
- Location
- Chula Vista, CA + 24 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Chandler, AZ + 21 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Regeneron Pharmaceuticals
- Location
- Sheffield, AL + 17 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Eli Lilly and Company
- Location
- Scottsdale, AZ + 36 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Regeneron Pharmaceuticals
- Location
- Huntsville, AL + 55 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Birmingham, AL + 59 other US sites
- Eligibility basics
- Ages 18+